You think that ZS-9 won't need to be separated? Its a zirconium ion. Tetracycline antibiotics have a label that they should be separated by two hours from anything that has Ca or Magnesium in them.
ZS-9 will have the same label as veltassa. I would go long RLYP and short ZSPH around their FDA date in May.
When you have a potassium of 7, who gives a poop when you take your statin. Are you kidding?
This is a very good point actually. Every company over the past two years that has received Lincoln Park funny money has either not increased in value since the financing was announced or has seen a reduction (in some cases up to 50% of the value of the stock). I think Lincoln Park holds the share price down so that they can maximize their profits at the expense of the company they are financing.
Oh great. Has INO decided to use IL-12 with the HPV vaccine? I thought they wanted to use IL-33. The one for cervical dysplasia has no additional adjuvant (besides the electroporation). The one for cervical cancer that they were going to test out, I didn't know if they decided on the IL-12 or the IL-33. IL-12 would be the way to go IMO, so that is a good decision on their part.
Yes. There are many things that can induce MANF to be expressed inside cells. They are all toxins that paralyze the cell's endoplasmic reticulum, or stop a cell from being able to make proteins, or activators of the glucose deprivation pathway, though.
If you take away an essential amino acid, and the cell can't make all the required proteins, MANF will be produced intracellularly as part of the ER stress pathway.
Similarly if a cell can't undergo the normal process of respiration because glucose stores are too low, they will activate the glucose/serum starvation pathways which are very similar to the ER stress pathways.
This is not an answer to healing disease though.
I thought it was prostate cancer. Anyway, Roche has their hands on so many pots, that this was one they could easily let go of.
ONCS finally starting to look like the better play out of INO and ONCS. Not really a "cancer vaccine." More an adjuvant. The trial looking at PD-1 inhibition and immunopulse has the big wigs involved (including UCSF and Merck). The two plays that are similar are ZIOP and ONCS, but ZIOP is partnered with Epizyme. ONCS with Merck... I think I would go with ONCS here...